Abstract
Objectives:Smoking is associated with an increased tumor mutational burden. As tumor mutational burden has been shown to correlate with response to immunotherapy (IO), we hypothesized that a history of smoking may be associated with better response to IO.Methods:We utilized a systematic review with stratified meta-analysis of randomized clinical trials of IO versus standard of care in patients with advanced solid organ malignancies.Results:Among 9 relevant studies, we found no significant difference in the benefit of IO, compared with other systemic therapies, between ever smokers (hazard ratio [HR], 0.77; 95% confidence interval [CI], 0.58-1.04; P=0.09) and never smokers (HR, 0.75; 95% CI, 0.67-0.86; P<0.0001) (test for difference P=0.83). We also observed no significant difference between current (HR, 0.92; 95% CI, 0.63-1.34; P=0.66; I2=67%) and never smokers (HR, 0.74; 95% CI, 0.59-0.93; P=0.01; I2=46%) (test for difference P=0.35).Conclusions:Stratified meta-analysis demonstrates that smoking status is not significantly associated with the response to IO in the treatment of advanced solid organ malignancies.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 711-716 |
| Number of pages | 6 |
| Journal | American Journal of Clinical Oncology: Cancer Clinical Trials |
| Volume | 42 |
| Issue number | 9 |
| DOIs | |
| State | Published - Sep 1 2019 |
Fingerprint
Keywords
- immunotherapy
- smoking
- tumor burden
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
Association between Smoking and Survival Benefit of Immunotherapy in Advanced Malignancies : A Systematic Review and Meta-Analysis. / Wallis, Christopher J.D.; Satkunasivam, Raj; Butaney, Mohit; Khan, Usman A.; Goldberg, Hanan A.; Freedland, Stephen J.; Patel, Sandip P.; Hamid, Omid; Pal, Sumanta K.; Klaassen, Zachary W A.
In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 42, No. 9, 01.09.2019, p. 711-716.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Association between Smoking and Survival Benefit of Immunotherapy in Advanced Malignancies
T2 - A Systematic Review and Meta-Analysis
AU - Wallis, Christopher J.D.
AU - Satkunasivam, Raj
AU - Butaney, Mohit
AU - Khan, Usman A.
AU - Goldberg, Hanan A.
AU - Freedland, Stephen J.
AU - Patel, Sandip P.
AU - Hamid, Omid
AU - Pal, Sumanta K.
AU - Klaassen, Zachary W A
PY - 2019/9/1
Y1 - 2019/9/1
N2 - Objectives:Smoking is associated with an increased tumor mutational burden. As tumor mutational burden has been shown to correlate with response to immunotherapy (IO), we hypothesized that a history of smoking may be associated with better response to IO.Methods:We utilized a systematic review with stratified meta-analysis of randomized clinical trials of IO versus standard of care in patients with advanced solid organ malignancies.Results:Among 9 relevant studies, we found no significant difference in the benefit of IO, compared with other systemic therapies, between ever smokers (hazard ratio [HR], 0.77; 95% confidence interval [CI], 0.58-1.04; P=0.09) and never smokers (HR, 0.75; 95% CI, 0.67-0.86; P<0.0001) (test for difference P=0.83). We also observed no significant difference between current (HR, 0.92; 95% CI, 0.63-1.34; P=0.66; I2=67%) and never smokers (HR, 0.74; 95% CI, 0.59-0.93; P=0.01; I2=46%) (test for difference P=0.35).Conclusions:Stratified meta-analysis demonstrates that smoking status is not significantly associated with the response to IO in the treatment of advanced solid organ malignancies.
AB - Objectives:Smoking is associated with an increased tumor mutational burden. As tumor mutational burden has been shown to correlate with response to immunotherapy (IO), we hypothesized that a history of smoking may be associated with better response to IO.Methods:We utilized a systematic review with stratified meta-analysis of randomized clinical trials of IO versus standard of care in patients with advanced solid organ malignancies.Results:Among 9 relevant studies, we found no significant difference in the benefit of IO, compared with other systemic therapies, between ever smokers (hazard ratio [HR], 0.77; 95% confidence interval [CI], 0.58-1.04; P=0.09) and never smokers (HR, 0.75; 95% CI, 0.67-0.86; P<0.0001) (test for difference P=0.83). We also observed no significant difference between current (HR, 0.92; 95% CI, 0.63-1.34; P=0.66; I2=67%) and never smokers (HR, 0.74; 95% CI, 0.59-0.93; P=0.01; I2=46%) (test for difference P=0.35).Conclusions:Stratified meta-analysis demonstrates that smoking status is not significantly associated with the response to IO in the treatment of advanced solid organ malignancies.
KW - immunotherapy
KW - smoking
KW - tumor burden
UR - http://www.scopus.com/inward/record.url?scp=85069735263&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85069735263&partnerID=8YFLogxK
U2 - 10.1097/COC.0000000000000577
DO - 10.1097/COC.0000000000000577
M3 - Article
VL - 42
SP - 711
EP - 716
JO - American Journal of Clinical Oncology
JF - American Journal of Clinical Oncology
SN - 0277-3732
IS - 9
ER -